The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women
- PMID: 18783534
- DOI: 10.1111/j.1743-6109.2008.00961.x
The current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women
Abstract
Introduction: Hypoactive sexual desire disorder (HSDD) is a common clinical problem in women, especially those who have experienced surgical menopause. Because androgen levels decline with age and drop dramatically following bilateral oophorectomy, it has been hypothesized that reduced levels of testosterone are related to diminished desire.
Aim: As presented at a continuing medical education satellite symposium during the 2008 annual meeting of the International Society for the Study of Women's Sexual Health, to review the current state of knowledge about the physiologic effects of testosterone in postmenopausal women, the effects of transdermal testosterone delivery in surgically menopausal women with HSDD, and ongoing studies of a transdermal testosterone gel.
Methods: A review of the pertinent literature, including recent presentations.
Main outcome measures: Results from the Women's International Study of Health and Sexuality; and studies utilizing the Brief Index of Sexual Functioning for Women, the Psychological General Well-Being Index, and validated instruments that assess female sexual function: the Sexual Activity Log, the Profile of Female Sexual Function, and the Personal Distress Scale.
Results: Surgically menopausal women receiving testosterone experience significant increases in total satisfying sexual activity vs. women receiving placebo, significant improvement in all domains of sexual function, and decreases in personal distress, with a favorable safety profile.
Conclusions: Testosterone deficiency may be considered among the underlying causes of HSDD. Currently, testosterone is available to women in the United States only via off-label prescribing or by unregulated compounding of testosterone preparations. New safety trials will examine the long-term safety of testosterone gel in surgically menopausal women with HSDD who are at high risk of cardiovascular disease or breast cancer.
Comment in
-
Editorial comments on "the current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women".J Sex Med. 2008 Sep 2;5 Suppl 4:177-8. doi: 10.1111/j.1743-6109.2008.00960.x. J Sex Med. 2008. PMID: 18783531 No abstract available.
Similar articles
-
Editorial comments on "the current outlook for testosterone in the management of hypoactive sexual desire disorder in postmenopausal women".J Sex Med. 2008 Sep 2;5 Suppl 4:177-8. doi: 10.1111/j.1743-6109.2008.00960.x. J Sex Med. 2008. PMID: 18783531 No abstract available.
-
Evaluation of the clinical relevance of benefits associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder.J Sex Med. 2007 Jul;4(4 Pt 1):1001-8. doi: 10.1111/j.1743-6109.2007.00526.x. J Sex Med. 2007. PMID: 17627745 Clinical Trial.
-
Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.J Sex Med. 2012 Apr;9(4):1134-48. doi: 10.1111/j.1743-6109.2011.02634.x. Epub 2012 Feb 3. J Sex Med. 2012. PMID: 22304681 Review.
-
Testosterone treatment for hypoactive sexual desire disorder in postmenopausal women.J Sex Med. 2007 Mar;4 Suppl 3:227-34. doi: 10.1111/j.1743-6109.2007.00449.x. J Sex Med. 2007. PMID: 17394595 Review.
-
The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women.Maturitas. 2009 Jul 20;63(3):213-9. doi: 10.1016/j.maturitas.2009.04.008. Epub 2009 May 31. Maturitas. 2009. PMID: 19487090 Review.
Cited by
-
Sexual function in elderly women: a review of current literature.Rev Obstet Gynecol. 2012;5(1):16-27. Rev Obstet Gynecol. 2012. PMID: 22582123 Free PMC article.
-
The testosterone metabolite 3α-diol enhances female rat sexual motivation when infused in the nucleus accumbens shell.J Sex Med. 2010 Nov;7(11):3598-609. doi: 10.1111/j.1743-6109.2010.01937.x. J Sex Med. 2010. PMID: 20646182 Free PMC article.
-
[Testosterone and psyche].Urologe A. 2010 Jan;49(1):43-6. doi: 10.1007/s00120-009-2197-8. Urologe A. 2010. PMID: 20057987 German.
-
Bremelanotide for Treatment of Female Hypoactive Sexual Desire.Neurol Int. 2022 Jan 4;14(1):75-88. doi: 10.3390/neurolint14010006. Neurol Int. 2022. PMID: 35076581 Free PMC article. Review.
-
Neuromodulation and female sexual function: does treatment for refractory voiding symptoms have an added benefit?Int Urogynecol J Pelvic Floor Dysfunct. 2009 Sep;20(9):1055-9. doi: 10.1007/s00192-009-0900-3. Epub 2009 May 14. Int Urogynecol J Pelvic Floor Dysfunct. 2009. PMID: 19440647
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials